Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VA Alternating With Low-dose CHA in Newly Diagnosed Unfit AML
NCT07172204Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2025
- Primary completion
- Jul 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, azacitidine, cladribine, homoharringtonine and cytarabine in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Negative rate of minimal residual lesions at 28 days. Started Sep 2025; status: recruiting.
02
Drugs
venetoclaxazacitidinecladribinehomoharringtoninecytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07172204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172204.